Brief: Elicera Gets Clearance To Use Highest ELC-301 Dose Ahead Of Phase IIa
09/09/2026 07:53
BRIEF-Elicera Gets Clearance To Use Highest ELC-301 Dose Ahead Of Phase IIa Sept 9 (Reuters) - Elicera Therapeutics AB ELIC.ST:
ELICERA THERAPEUTICS RECEIVES SAFETY COMMITTEE RECOMMENDATION TO USE HIGHEST ELC-301 DOSE AS CARMA MOVES TOWARD PHASE IIA IN B-CELL LYMPHOMA
Source text: ID:nWkr8x9LLc
Further company coverage: ELIC.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Elicera Therapeutics AB
See all newsBrief: Elicera Therapeutics Completes Phase I Part Of Carma Study
Brief: Elicera Therapeutics Gets Medical Products Agency Approval To Advance CARMA Study
Brief: Elicera Gets Clearance To Use Highest ELC-301 Dose Ahead Of Phase IIa
Brief: Elicera Gets First Patent Allowance For ELC-201
Brief: Elicera Receives Notice Of Allowance For U.S. Patent Application